Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
161 hedge funds and large institutions have $1.45B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 52 increasing their positions, 53 reducing their positions, and 12 closing their positions.
466% more call options, than puts
Call options by funds: $18.3M | Put options by funds: $3.23M
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
10% more funds holding
Funds holding: 147 → 161 (+14)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 53
8% less capital invested
Capital invested by funds: $1.58B → $1.45B (-$127M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$23.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$12.8M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$8.28M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$6.69M |
| 5 |
AC
Armistice Capital
New York
|
+$6.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$35.6M |
| 2 |
DM
Deerfield Management
New York
|
-$16.9M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$14.2M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$11.3M |
| 5 |
Alkeon Capital Management
New York
|
-$8.62M |
DCPH Hedge Fund Activity: Q3 2021 in Review
161 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2021, worth a combined $1.45B — down 8% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new DCPH positions and 12 closed out — a net gain of 15 holders — while 52 added to existing stakes and 53 trimmed.
The largest buyer was Logos Global Management, adding an estimated $23.9M. The largest seller was OrbiMed, cutting an estimated $35.6M.
- 161 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2021, up from 147 in Q2 2021.
- Funds reported $1.45B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 8% quarter-over-quarter.
- 27 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 12 closed out, a net change of +15 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Logos Global Management, an estimated $23.9M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was OrbiMed, an estimated $35.6M sold.
Based on aggregated 13F filings for Q3 2021.